RS-3540 · Evidence-based safety and harm-reduction overview.
| Also known as | RS-3540 |
| Category | Nootropic |
| chemical_family | 2-oxo-1-pyrrolidine acetamide derivative |
| first_marketed | 1970s in France and Belgium |
| US legal status | Not FDA-approved; sold gray-market as research chemical in the United States. Approved pharmaceutical in some EU countries. |
Racetam compound, proposed to affect membrane fluidity and cell signaling. Derived from piracetam chemistry, pramiracetam is hypothesized to modulate neuronal communication without direct receptor binding. Used off-label in some European countries as a cognitive enhancer.
Pramiracetam is theorized to enhance cell membrane fluidity and improve neurotransmitter vesicle dynamics, potentially increasing acetylcholine release. Animal studies suggest modulation of phosphatidylserine and lipid composition in neural membranes. Human mechanism of action remains unclear and not proven.
Synthesized as part of the racetam family in the 1970s-1980s. Developed primarily in Europe with most research conducted in France and Belgium. Licensed as a pharmaceutical in some EU nations but never pursued FDA approval in the US.
Limited clinical research; some studies on older adults and memory. Quality and replication concerns in available literature. Most data originates from the 1990s with small sample sizes and variable methodology.
Pharmaceutical forms studied at 600-2400 mg daily in divided doses. Gray-market availability offers 500-800 mg capsules; actual dosing protocols in clinical trials varied significantly.
This is general research/context information, not medical advice or a recommended protocol.
Sometimes stacked with choline sources (Alpha-GPC, CDP-choline) in anecdotal reports, though no controlled studies support this combination. Commonly avoided with other gray-market racetams due to unverified additive effects.
Citicoline (CDP-choline). FDA-recognized, well-studied cholinergic with evidence for memory support and neuroprotection; legally available as supplement in US.
See our recommended pickIf you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.
Compare testing optionsNo. Pramiracetam is a gray-market research chemical in the United States and not approved as a drug or dietary supplement by the FDA.
Animal and limited clinical studies suggest possible effects on learning and memory, but human evidence is weak and replication is poor.
Pramiracetam has a bulkier chemical structure but theoretical advantages in bioavailability; direct comparative trials in humans are absent.
Yes, independent labs can perform HPLC or mass spectrometry; expect 150-400 USD for comprehensive testing.
Estimated 2-3 hours based on limited pharmacokinetic data, but human studies are scarce and estimates may not be reliable.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.